American Endovascular

What American Endovascular does

American Endovascular is a privately held medical device company founded in 2014 and headquartered in Glen Rock, New Jersey. According to its own short description, the company develops endovascular neurosurgery solutions aimed at preventing intracranial aneurysms and preventing amputation in patients, placing it in the neurovascular intervention and peripheral vascular care segments of the medical device industry. The firm is founder-led, with Raymond Figueroa serving as Founder and Chief Executive Officer, and operates with a workforce in the 101–250 employee band, consistent with a small-to-mid-cap privately held specialty medical device company.

The company's product portfolio, underlying technology stack, pricing model, go-to-motion, and customer composition are not disclosed in the available source data — the firm's public website resolves to a loading/verification page, and no product catalog, regulatory clearances, patent portfolio, partnerships, or customer references are present in the input. Consequently, revenue mechanics (whether the company sells devices, consumables, or procedural services), distribution channels, and end-customer segments (hospital systems, ambulatory surgery centers, specialty vascular practices) cannot be verified from the evidence provided. The short description framing — "endovascular neurosurgery solutions for preventing intracranial aneurysms and amputation of patients" — suggests a device-and-procedure-oriented business serving interventional neuroradiology and vascular surgery specialists, but the supporting evidence is limited to that single descriptor.

From an investment standpoint, the firm is best characterized as a niche, founder-driven private medical device company with a stated clinical focus in neurovascular and limb-salvage intervention. Its 2014 vintage and 101–250 employee scale indicate an established operating history, but the absence of disclosed funding history, revenue figures, product approvals, or strategic transactions in the source material constrains any deeper analytical triangulation. The primary data gaps — financial performance, product detail, regulatory pathway status, and customer profile — should be treated as material diligence items rather than inferred.

Name

American Endovascular

Website

https://americanendovascular.com

Company type

Private

Founded year

2014

Headcount range

101–250 employees

Short description

American Endovascular is a privately held, founder-led medical device company founded in 2014 in Glen Rock, New Jersey, that develops endovascular neurosurgery solutions aimed at preventing intracranial aneurysms and patient amputation, serving the neurovascular and vascular surgery markets.

Ownership category

akta.pro rank

Product category

Neurovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

akta.pro secondary industry

Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)

Keywords

• Endovascular neurosurgery
• Neurovascular devices
• Intracranial aneurysm treatment
• Cerebral aneurysm implants
• Vascular medical devices

Headquarters

HQ city

Glen Rock

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Core offering

American Endovascular develops endovascular neurosurgery solutions, including medical devices and implants, designed to prevent intracranial aneurysms and avoid amputation of patients. The company manufactures and supplies specialized neurovascular products used by neurosurgeons and healthcare facilities for the treatment of cerebral aneurysms.

Differentiator

Problem solved

Functional benefit

Products and services

• Endovascular Neurosurgery Solutions for Intracranial Aneurysm Prevention

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Penumbra: Penumbra is a publicly traded neurovascular device company specializing in catheter-based thrombectomy and embolization systems used in the treatment of stroke and intracranial aneurysms — directly comparable to American Endovascular's stated endovascular neurosurgery focus.

Others

• Viz.ai: Viz.ai provides AI-driven clinical workflow software that routes stroke and aneurysm patients to neurovascular specialists. While not a device peer, it operates in the same endovascular neurovascular care pathway and could be a software/ecosystem adjacent participant.

Broad incumbents

• MicroPort Scientific: MicroPort's neurovascular business (including the acquired Blockade Medical assets) sells coils and flow-diverting devices for intracranial aneurysm treatment, representing a global broad incumbent peer with overlapping endovascular neurosurgery offerings.
• Stryker (Neurovascular): Stryker's Neurovascular division (built around the acquired Target Vascular and Stryker Neurovascular franchises) sells coils, flow diverters, and access devices for intracranial aneurysm and stroke treatment, making it the dominant incumbent peer.
• Medtronic: Medtronic's Neurovascular portfolio (historically including Pipeline Embolization Device and Solitaire) addresses intracranial aneurysm and acute ischemic stroke intervention, overlapping directly with American Endovascular's endovascular neurosurgery positioning.
• Cerenovus (Johnson & Johnson MedTech): Cerenovus is J&J's neurovascular business focused on hemorrhagic and ischemic stroke intervention devices, including coils and flow diverters used in aneurysm treatment — a broad incumbent peer in the same clinical category.

Emerging players

• Rapid Medical: Rapid Medical develops adjustable, minimally invasive neurovascular devices for aneurysm and stroke treatment. As a smaller, venture-backed specialist, it is a closely comparable emerging peer to American Endovascular.
• Imperative Care: Imperative Care focuses on catheter-based ischemic stroke and vascular access technologies, with an endovascular procedural platform that overlaps with the aneurysm-access and delivery-device components of American Endovascular's work.
• Route 92 Medical: Route 92 Medical is developing catheter systems for neurovascular intervention including acute ischemic stroke, positioning it as a venture-stage peer developing endovascular delivery and access technology in the same clinical space.
• InNeuroCo: InNeuroCo develops next-generation intermediate and access catheters for neurovascular procedures, including stroke and aneurysm interventions — a smaller, niche peer building devices adjacent to American Endovascular's stated focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/amendovascular
• Facebookfacebook.com/AmericanEndovascular

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about American Endovascular